$155.33
0.21% today
NYSE, May 09, 06:44 pm CET
ISIN
US4781601046
Symbol
JNJ

Johnson & Johnson Stock price

$155.66
+5.66 3.77% 1M
+0.19 0.12% 6M
+11.04 7.63% YTD
+6.71 4.50% 1Y
-21.67 12.22% 3Y
+6.96 4.68% 5Y
+54.19 53.40% 10Y
NYSE, Closing price Thu, May 08 2025
-1.64 1.04%
ISIN
US4781601046
Symbol
JNJ
Sector
Industry

Key metrics

Market capitalization $375.12b
Enterprise Value $388.59b
P/E (TTM) P/E ratio 17.30
EV/FCF (TTM) EV/FCF 19.08
EV/Sales (TTM) EV/Sales 4.35
P/S ratio (TTM) P/S ratio 4.20
P/B ratio (TTM) P/B ratio 4.79
Dividend yield 3.15%
Last dividend (FY24) $4.91
Revenue growth (TTM) Revenue growth -0.37%
Revenue (TTM) Revenue $89.33b
EBIT (operating result TTM) EBIT $21.29b
Free Cash Flow (TTM) Free Cash Flow $20.37b
Cash position $38.78b
EPS (TTM) EPS $9.00
P/E forward 14.22
P/S forward 4.11
EV/Sales forward 4.26
Short interest 0.87%
Show more

Create a Free Account to create an Johnson & Johnson alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Johnson & Johnson Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Johnson & Johnson forecast:

12x Buy
48%
13x Hold
52%

Analyst Opinions

25 Analysts have issued a Johnson & Johnson forecast:

Buy
48%
Hold
52%

Financial data from Johnson & Johnson

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
89,331 89,331
0% 0%
100%
- Direct Costs 28,375 28,375
0% 0%
32%
60,956 60,956
1% 1%
68%
- Selling and Administrative Expenses 15,428 15,428
2% 2%
17%
- Research and Development Expense 16,945 16,945
11% 11%
19%
28,583 28,583
6% 6%
32%
- Depreciation and Amortization 7,296 7,296
2% 2%
8%
EBIT (Operating Income) EBIT 21,287 21,287
7% 7%
24%
Net Profit 21,810 21,810
25% 25%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Johnson & Johnson directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Johnson & Johnson Stock News

Positive
Reuters
about 5 hours ago
Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal in a late-stage study on patients 12 years and older.
Neutral
PRNewsWire
about 5 hours ago
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill SPRING HOUSE, Pa. , May 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JN...
Positive
24/7 Wall Street
about 6 hours ago
Investors love dividend stocks, especially high-yield ones, because they offer significant income streams and have substantial total return potential.
More Johnson & Johnson News

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Head office United States
CEO Joaquin Duato
Employees 138,100
Founded 1887
Website www.jnj.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today